
AI Derived Emerging Targets at ESMO 2026 #oncology #CancerCare #esmo #HealthcareAI

Easing oncology outcomes decision making

AI Derived Emerging Targets at ESMO 2026 #oncology #CancerCare #esmo #HealthcareAI

The other side of ASCO 2026. Used Gen AI to synthesize ASCO 2026 KOL negative commentary into a simple signal map.

NEW ASCO Guidelines Assistant tool leverages Google Cloud Vertex AI platform & Gemini models, enabling oncology clinicians to quickly access evidence-based clinical guidelines.


Immune cell effector-associated neurotoxicity syndrome (ICANS) is a less well understood entity related to cytokine disruption of BBB and comprising diverse neurological symptoms. ICANS was rare (<10%) and no ICANS 3 or more was observed. (pic from Sands Cancer 2024) 🧵12/15

Do ΔORR and ΔDoR Predict PFS and OS Hazard Ratios Across Cancer RCTs? #CancerTrials #RCTs #MedicalAI

Deep research cost evaluation of the recent Stage IV NSCLC With Driver Alterations: ASCO Living Guideline v2024.3 #nsclc #ASCO #lungcancer #Oncology




Generative Reward Models Self-Taught Reasoning (STAR) in AI Training for cancer clinical trials



Biomarkers, Molecular Targets, and Methods of Detection for Precision Medicines in NSCLC (ESMO guideline)

🫁 NCCN guideline updated 🫁 🫁 Part-1, NSCLC 🫁 🌟 Version 9.2024 — September 9, 2024 🌟 📌 Ver. 8 was updated on August 23, 2024, so went to ver. 9 in about 2 weeks, right in the middle of WCLC 2024.

#WCLC24 @IASLC was a joy. Thank @one_interrobang @donnashort @marklewismd @HHorinouchi and all

🫁 Lung Cancer - ICIs data 🫁 🌟 Summary of 5-year (long follow-up) data 🌟 NSCLC (NSQ & SQ) #Immunotherapy #Lungcancer #longfollowup #LCSM